Valuation: Genmab A/S

Capitalization 83.86B 13.16B 11.24B 10.49B 9.7B 18B 1,129B 20.17B 126B 47.7B 527B 49.34B 48.33B 1,932B P/E ratio 2025 *
13.3x
P/E ratio 2026 * 11.3x
Enterprise value 60.39B 9.47B 8.09B 7.55B 6.98B 12.96B 813B 14.52B 90.49B 34.34B 379B 35.53B 34.8B 1,391B EV / Sales 2025 *
2.58x
EV / Sales 2026 * 1.94x
Free-Float
95.94%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.17%
1 week+4.03%
Current month+3.99%
1 month-8.53%
3 months+7.80%
6 months-14.50%
Current year-8.38%
More quotes
1 week 1,275
Extreme 1275
1,377
1 month 1,275
Extreme 1275
1,502.5
Current year 1,157
Extreme 1157
1,672.5
1 year 1,157
Extreme 1157
1,975
3 years 1,157
Extreme 1157
3,327
5 years 1,157
Extreme 1157
3,327
10 years 501
Extreme 501
3,327
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 31/05/2010
Director of Finance/CFO 47 29/02/2020
Chief Tech/Sci/R&D Officer - 15/08/2024
Director TitleAgeSince
Director/Board Member 74 31/10/2003
Director/Board Member 58 31/12/2014
Director/Board Member 74 31/12/2014
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.17%+4.03%-22.19%-45.17% 13.16B
+0.02%-2.46%+15.63%+33.12% 33.25B
+0.80%-0.42%+90.94%-36.12% 28.1B
-0.20%+3.02%+38.53%-33.00% 27.49B
+0.16%-1.54%+37.65%+315.15% 18.26B
+3.09%+4.91%+202.68%+2,273.00% 17.07B
+0.78%+0.97%+140.26%-67.62% 13.32B
0.00%+18.32%+199.59%+347.25% 12.55B
-0.02%-2.28%+95.44%+109.84% 11.87B
+1.98%+6.32%+137.96% - 9.99B
Average +0.66%+3.66%+93.65%+321.83% 18.51B
Weighted average by Cap. +0.55%+2.65%+80.38%+273.65%
See all sector performances

Financials

2025 *2026 *
Net sales 23.43B 3.68B 3.14B 2.93B 2.71B 5.03B 315B 5.63B 35.11B 13.32B 147B 13.78B 13.5B 540B 27.04B 4.24B 3.62B 3.38B 3.13B 5.8B 364B 6.5B 40.52B 15.38B 170B 15.91B 15.58B 623B
Net income 6.65B 1.04B 892M 832M 770M 1.43B 89.56B 1.6B 9.97B 3.78B 41.78B 3.92B 3.83B 153B 8B 1.26B 1.07B 1B 925M 1.72B 108B 1.92B 11.99B 4.55B 50.24B 4.71B 4.61B 184B
Net Debt -23.47B -3.68B -3.15B -2.94B -2.72B -5.04B -316B -5.65B -35.18B -13.35B -147B -13.81B -13.53B -541B -31.41B -4.93B -4.21B -3.93B -3.63B -6.74B -423B -7.55B -47.07B -17.86B -197B -18.48B -18.1B -723B
More financial data * Estimated data
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).
Employees
2,638
More about the company
Date Price Change Volume
09/07/25 1,371.50 kr +0.59% 89,883
08/07/25 1,363.50 kr +4.24% 171,484
07/07/25 1,308.00 kr +0.73% 110,307
04/07/25 1,298.50 kr +0.50% 59,765
03/07/25 1,292.00 kr -0.31% 75,591

Delayed Quote Nasdaq Copenhagen, July 09, 2025 at 03:10 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
1,363.50DKK
Average target price
1,936.20DKK
Spread / Average Target
+42.00%
Consensus

Quarterly revenue - Rate of surprise